Adamas Announces New Employment Inducement Grant
September 12, 2018 16:30 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted six new...
Adamas Announces New Employment Inducement Grant
August 08, 2018 16:30 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted four new...
Adamas Reports Second Quarter 2018 Financial Results
August 02, 2018 16:01 ET
|
Adamas Pharmaceuticals, Inc.
- GOCOVRI™ (amantadine) extended release capsules product sales reached $7.6 million for the second quarter - EMERYVILLE, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc....
Adamas Pharmaceuticals Launches “Dyskinesia Is A Jerk™,” a Campaign to Raise Awareness and Highlight the Impact of Parkinson’s Disease Dyskinesia
August 01, 2018 09:00 ET
|
Adamas Pharmaceuticals, Inc.
- Despite significant impact on daily life and the ability to treat primary symptoms of Parkinson’s disease dyskinesia (uncontrolled jerking or twisting movements), symptoms are often not recognized...
Adamas to Announce Second Quarter 2018 Financial Results and Host Conference Call on August 2, 2018
July 26, 2018 12:05 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., July 26, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report second quarter 2018 financial results on Thursday,...
Adamas Announces New Employment Inducement Grant
July 09, 2018 16:39 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the compensation committee of the company’s board of directors granted two new...
Adamas Presents New Data Analysis Demonstrating that GOCOVRI™ Reduces Transitions between Dyskinesia and OFF Episodes Throughout the Day
June 22, 2018 09:12 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., June 22, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the presentation of new data analysis of GOCOVRI™ (amantadine) extended release...
Adamas Announces New Employment Inducement Grant
June 08, 2018 17:55 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., June 08, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the compensation committee of the company’s board of directors granted six new...
Adamas to Present at Two Upcoming Investor Conferences
June 07, 2018 16:30 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., June 07, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., the company’s Founder, Chairman and Chief Executive...
Adamas Announces Publication of Pharmacokinetic Data for GOCOVRI™ in Clinical Pharmacokinetics
May 24, 2018 09:05 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., May 24, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that pharmacokinetic (PK) data regarding GOCOVRI™ (amantadine) extended release...